The company is on a clear path to profitability with strong revenue growth and margin expansion. Traders should monitor the execution of commercial initiatives, HYDROS adoption rates, and progress in the prostate cancer clinical trials as key catalysts for future valuation.
Price Chart
Executive Summary
PROCEPT BioRobotics disclosed its 2026 Analyst Day presentation, highlighting strong financial guidance with 2026 revenue projected between $390M and $410M (27-33% growth), improved gross margins targeting 65% in 2026 and 68-70% in 2027, and a clear path to profitability with adjusted EBITDA expected to turn positive in Q4 2026 and reach $25-30M gain in 2027. The company emphasized commercial execution, HYDROS system adoption, and expansion into prostate cancer treatment.
Key Facts
- 2026 revenue guidance of $390M to $410M, representing 27% to 33% growth
- 2027 revenue growth expected at 25% to 30%
- 2026 gross margin guidance of 65%, targeting 68-70% in 2027
- 2026 adjusted EBITDA loss guidance of $30M to $17M, with 2027 adjusted EBITDA gain of $25M to $30M
- Positive EBITDA expected in Q4 2026
- Handpiece pricing increased to $3,500, a 9% YoY increase
- 60,000 to 64,000 procedures projected for 2026
- HYDROS system expected to represent majority of install base by end of 2026
Financial Impact
Revenue growth of 27-33% in 2026 and 25-30% in 2027, with gross margin expansion to 65% in 2026 and 68-70% in 2027, leading to EBITDA profitability by Q4 2026
Risk Factors
- Execution risk in achieving projected procedure growth and commercial initiatives
- Potential delays in HYDROS system adoption or prostate cancer clinical trial progress
- Market competition in the BPH and prostate cancer treatment space
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001588978-26-000007 |
| Document: prct-20260226.htm | 0001588978-26-000007 |
| Document: 0001588978-26-000007-index-headers.html | 0001588978-26-000007 |
| Document: 0001588978-26-000007-index.html | 0001588978-26-000007 |
| Document: 0001588978-26-000007.txt | 0001588978-26-000007 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 11, 2026 16w ago | Institutional Cluster | $27.69 $19.75 | ▼ −28.67% | ▼ −30.57% | $17.16 (−38.03%) |
Jun 10, 2026 16w ago | Insider Cluster | $27.69 $19.75 | ▼ −28.67% | ▼ −30.57% | $17.16 (−38.03%) |
Jun 10, 2026 16w ago | Insider Cluster | $27.69 $19.75 | ▼ −28.67% | ▼ −30.57% | $17.16 (−38.03%) |
Jun 10, 2026 16w ago | Insider Cluster | $27.69 $19.75 | ▼ −28.67% | ▼ −30.57% | $17.16 (−38.03%) |
Mar 10, 2026 29w ago | Insider Cluster | $24.17 $23.87 | ▼ −1.24% | ▼ −1.09% | $17.16 (−29.00%) |
Mar 6, 2026 30w ago | 8-K | $24.22 $23.78 | ▼ −1.82% | ▲ +0.23% | $17.16 (−29.15%) |
Mar 6, 2026 30w ago | Insider Cluster | $24.22 $23.78 | ▼ −1.82% | ▲ +0.23% | $17.16 (−29.15%) |
Mar 6, 2026 30w ago | Insider Cluster | $24.22 $23.78 | ▼ −1.82% | ▲ +0.23% | $17.16 (−29.15%) |
Feb 26, 2026 31w ago | 8-K | $23.63 $25.07 | ▲ +6.09% | ▲ +12.50% | $17.16 (−27.38%) |
Feb 25, 2026 31w ago | 8-K | $27.84 $24.94 | ▼ −10.42% | ▼ −5.18% | $17.16 (−38.36%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access